T cell redirecting therapy for relapsed multiple myeloma.

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma treatment has advanced with immunomodulatory drugs, proteasome inhibitors, and CD38 antibodies.
• Despite progress, relapsed multiple myeloma patients often face poor prognoses.
• Chimeric antigen receptor (CAR) T-cells and T-cell engagers (TCE) represent significant therapeutic breakthroughs.

Purpose of the Study:

• To review clinical outcomes of novel immunotherapeutic agents in relapsed multiple myeloma.
• To analyze the toxicities, optimal sequencing, and role of CAR T-cells and TCEs.
• To discuss supportive care and future directions in multiple myeloma immunotherapy.

Main Methods:

• Literature review of clinical outcomes for immunotherapies in relapsed multiple myeloma.
• Analysis of data on CAR T-cells and T-cell engagers efficacy and safety.
• Synthesis of information on treatment sequencing and supportive care strategies.

Main Results:

• CAR T-cells and TCEs have demonstrated improved survival in triple and penta-class refractory multiple myeloma.
• These novel agents are associated with specific toxicities that require careful management.
• Optimal sequencing and integration into the existing treatment landscape are crucial for maximizing patient benefit.

Conclusions:

• Immunotherapy, including CAR T-cells and TCEs, has transformed the treatment of relapsed multiple myeloma.
• Understanding associated toxicities and implementing effective supportive care are essential.
• Emerging developments promise further advancements in managing this complex disease.